Skip to main content
Back to News
CataX AI raises seed funding from Qiming for clinical drug development
Funding
2 min read
CN

CataX AI raises seed funding from Qiming for clinical drug development

The AMW Read

The funding introduces a clinical-development entrant with an asset ownership model, but its operational and clinical results remain unproven.
NoveltySignificance
Healthcare & Bio · Player Map

CataX AI raises seed funding from Qiming for clinical drug development

Shanghai-based CataX AI has raised a seed round exclusively from Qiming Venture Partners, according to Investment China. The funding amount was not disclosed. Founded in July 2026, the company plans to use AI agents in early drug development. It aims to license or co-develop preclinical and early clinical assets, advance them toward human proof of concept, and seek partners for later development and commercialization. Founder Zilong Wang previously researched medical AI at Microsoft Research Asia.

The company adds a clinical-development business to a healthcare AI field that also includes drug discovery, diagnostics, and clinical workflow tools. Its proposed model places one clinical development lead in charge of a project, coordinating AI agents and external experts. Agents would assist with research, document drafting, and data processing, while people retain responsibility for key decisions. CataX is still reorganizing workflows and addressing technical, risk-control, and regulatory requirements. The source says the agents' performance in asset research remains to be validated.

For investors, the test is whether CataX can advance assets through early clinical proof of concept with a smaller team while meeting clinical and regulatory demands. The company also faces a staffing constraint: project leads need both clinical expertise and an understanding of AI. Wang plans to retain expert feedback, decision records, and outcomes in a shared system so future teams can use that experience. The proposed efficiency gains remain a goal; the report provides no measured savings or completed clinical results.

#CataXAI #HealthcareAI #ClinicalTrials #AIAgents #VentureCapital

#CataX AI#Qiming Venture Partners#clinical development#AI agents#related:Qiming Venture Partners
Read Original

How This Connects

Based on Healthcare & Bio · Player Map

  1. 36m agoCataX AI raises seed funding from Qiming for clinical drug development · THIS ARTICLE
  2. 3w agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  3. 3w agoWarp Sciences, founded by former OpenAI science lead Kevin Weil, raises $215M to automate drug-chemistry labsWarp Sciences
  4. 3w agoWarp Sciences raises $215 million for robotic drug-discovery labsWarp Sciences

Related News

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard